How effective is regorafenib in treating bowel cancer?

Regorafenib is a multi-target tyrosine kinase inhibitor that has been approved for the treatment of advanced colorectal cancer (CRC) and other tumors. Its main mechanism of action is to inhibit the growth of cancer by inhibiting the angiogenesis, tumor cell proliferation and metastasis process of tumor cells. The therapeutic effect of regorafenib on patients with advanced bowel cancer has been verified in clinical trials. Especially for those patients who have received first-line and second-line treatments but still progress, regorafenib provides an effective treatment option.

1. The efficacy of regorafenib in advanced colorectal cancer

The main application of regorafenib is to treat patients with advanced colorectal cancer (CRC), especially those who have received chemotherapy and targeted therapies (such as bevacizumab and cetuximab) and whose disease has progressed. In clinical studies, regorafenib has shown significant efficacy. In a pivotal Phase III trial (CORRECT trial), regorafenib significantly prolonged overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with advanced colorectal cancer. The results of this study show that regorafenib can effectively delay tumor progression and provide a new treatment method.

Specifically, the median progression-free survival (PFS) was 2.0 months with regorafenib compared with 1.7 months with placebo. Although this difference may seem small, from a clinical perspective, extending the tumor's progression-free survival means that the patient's quality of life is improved and may give the patient more time to receive other treatments. Therefore, regorafenib is considered an important drug to prolong the survival of patients with advanced colorectal cancer.

2. The mechanism of action of regorafenib

Regofenib is a multi-target drug that inhibits multiple kinases. It mainly works by inhibiting various signaling pathways related to cancer cell proliferation and tumor angiogenesis. The targets of regorafenib include VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), c-Kit and RET, etc. Inhibition of these targets helps reduce tumor blood supply and inhibit tumor proliferation and metastasis.

In particular, regorafenib effectively reduces the tumor's dependence on blood supply by inhibiting the angiogenesis process in the tumor microenvironment, which not only inhibits tumor growth but also effectively slows the spread of cancer cells. This multi-target mechanism of action gives regorafenib unique advantages in the treatment of drug-resistant colorectal cancer.

3. Side effects and management of regorafenib

Although regorafenib has shown significant efficacy in the treatment of bowel cancer, it is also associated with certain side effects. Common side effects include fatigue, high blood pressure, hand-foot skin reaction, decreased appetite, diarrhea, and mouth ulcers. Among them, hypertension is one of the most common serious side effects of regorafenib. Patients need to monitor their blood pressure regularly during treatment and intervene when necessary.

In addition, regorafenib may also cause abnormal liver function, so patients need to check their liver function regularly during use to ensure that no serious liver damage occurs. For hand and foot skin reactions, patients can relieve symptoms by keeping the skin clean and applying moisturizer. If a patient experiences serious side effects, treatment may need to be paused or the dose adjusted.

Overall, the therapeutic effect of regorafenib in patients with advanced colorectal cancer is significant. Through its multi-target mechanism of action, it can effectively inhibit tumor growth and metastasis, significantly extend the progression-free survival of patients, and provide new treatment options for patients who have received other treatments but still progress. Although it has certain side effects, they can be effectively managed under the guidance of a doctor. For patients with intestinal cancer, regorafenib undoubtedly provides an effective treatment method, especially for those advanced patients who are difficult to accept traditional chemotherapy, regorafenib has important clinical value.

Reference materials:https://www.stivarga-us.com/